University of California San Francisco UCSF
Welcome,         Profile    Billing    Logout  
 7 Trials 
7 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lodish, Maya B
NCT05228184: Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)

Active, not recruiting
4
126
US
Tirosint®-SOL, levothyroxine sodium oral solution (liquid), Levothyroxine Sodium, levothyroxine sodium tablets
IBSA Institut Biochimique SA, Cromsource
Congenital Hypothyroidism
04/25
04/25
NCT03708900 / 2018-001522-25: Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients with Cushing's Disease

Recruiting
2
12
Europe, US
LCI699, osilodrostat
RECORDATI GROUP
Cushing's Disease
11/25
11/25
Blakely, Collin
NCT03433469: Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

Active, not recruiting
2
27
US
Osimertinib, AZD-9291, Tagrisso, Therapeutic Conventional Surgery
University of California, San Francisco, AstraZeneca
Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer
01/23
10/26
NCT04410796: Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Recruiting
2
571
US
Osimertinib, Carboplatin, Pemetrexed
Memorial Sloan Kettering Cancer Center, AstraZeneca, Guardant Health, Inc.
Metastatic Non-small Cell Lung Cancer
05/25
05/25
NCT05375994: Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

Active, not recruiting
1/2
85
US
avutometinib (VS-6766) and adagrasib, KRAS G12C Inhibitor, adagrasib, KRAZATI®
Verastem, Inc., Mirati Therapeutics Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease
12/24
01/25
NCI-2019-05913, NCT04085315: Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Recruiting
1
38
US
Osimertinib, Tagrisso, Alisertib, MLN8237
Collin Blakely, Puma Biotechnology, Inc.
Lung Cancer Metastatic, EGFR Gene Mutation
12/26
12/26
NCT05435846: Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

Terminated
1
3
US
Capmatinib, INC280, Trametinib, TMT212, Mekinist
Collin Blakely, Novartis
Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer
11/23
05/24
Callahan, Patrick M
No trials found
Rankin, Katherine P
No trials found

Download Options